Circulating cell-free DNA in cancer

Methods in Molecular Biology

Volumn 1160, Issue , 2014, Pages 133-145

  Pinzani, Pamela ^a   Salvianti, Francesca ^a   Orlando, Claudio ^a   Pazzagli, Mario ^a  

^a NONE

Author keywords

BRAFV600E; Cell free DNA; Circulating markers; Plasma; qPCR

Indexed keywords

CELL DNA; CELL FREE DNA; DNA FRAGMENT; UNCLASSIFIED DRUG; DNA;

ALLELE; ARTICLE; BREAST CANCER CELL LINE; CANCER PATIENT; CONTROLLED STUDY; DNA DETERMINATION; FOLLOW UP; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC MUTATION; THYROID CANCER; BLOOD; BLOOD SAMPLING; CELL FREE SYSTEM; GENETICS; METABOLISM; MUTATION; NEOPLASM; POLYMERASE CHAIN REACTION; PROCEDURES;

ALLELES; BLOOD SPECIMEN COLLECTION; CELL-FREE SYSTEM; DNA, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 84921424801     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0733-5_13     Document Type: Article

References (29)

1. Tsang JC, Lo YM (2007) Circulating nucleic acids in plasma/serum. Pathology 39: 197-207.
2. Fleischhancker M, Schmidt B (2006) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232.
3. Mandel P, Metais P (1948) Les acides nucléiques du plasma sanguine chez l'homme. C R Acad Sci Paris 142: 241-243.
4. Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650.
5. Georgiou CD, Patsoukis N, Papapostolou I (2005) Assay for the quantification of smallsized fragmented genomic DNA. Anal Biochem 339: 223-230.
6. Holdenrieder S, Stieber P (2004) Apoptotic markers in cancer. Clin Biochem 37: 605-617.
7. Nagata S (2005) DNA degradation in development and programmed cell death. Cell Death Differ 10: 108-116.
8. Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665.
9. Gormally E, Caboux E, Vineis P et al (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635: 105-117.
10. Gahan PB, Swaminathan R (2008) Circulating nucleic acids in plasma and serum. Recent developments. Ann N Y Acad Sci 1137: 1-6.
11. Gahan PB, Anker P, Stroun M (2008) Metabolic DNA as the origin of spontaneously released DNA? Ann N Y Acad Sci 1137: 7-17.
12. Stroun M, Anker P, Lyautey J et al (1987) Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23: 707-712.
13. Jung M, Klotzek S, Lewandowski M et al (2003) Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49: 1028-1029.
14. Lam NYL, Rainer TH, Chiu RWK et al (2004) EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 50: 256-257.
15. Chiang P, Beer DG, Wei W et al (1999) Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res 5: 1381-1386.
16. Chiu RWK, Poon LLM, Lau TK et al (2001) Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 47: 1607-1613.
17. Swinkels DW, Wiegerinck E, Steegers EA et al (2003) Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem 49: 525-526.
18. Lui YY, Chik KW, Lo YM (2002) Does centrifugation cause the ex vivo release of DNA from blood cells? Clin Chem 48: 2074-2076.
19. Kopreski MS, Benko FA, Kwee C et al (1997) Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 76: 1293-1299.
20. Lee T, LeShane ES, Messerlian GM et al (2002) Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol 187: 1217-1221.
21. Kopreski MS, Benko FA, Kwak LW et al (1999) Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 5: 1961-1965.
22. Sozzi G, Roz L, Conte D et al (2005) Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 97: 1848-1850.
23. Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411: 1611-1624.
24. van der Vaart M, Pretorius PJ (2008) Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137: 18-26.
25. Pinzani P, Salvianti F, Cascella R et al (2010) Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta 411: 1319-1324.
26. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
27. Vdovichenko KK, Markova SI, Belokhvostov AS (2004) Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci 1022: 228-231.
28. Cradic KW, Milosevic D, Rosenberg AM et al (2009) Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 94: 5001-5009.
29. Chuang TC, Chuang AY, Poeta L et al (2010) Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 32: 229-234.